An interventional study of telemedicine in Dementia, sponsored by University Hospital, Toulouse. Completed at 2 sites in France. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2023-06-01.
Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Supportive care
Telemedicine may facilitate adequate treatment of Neuropsychiatric symptoms (NPS) by identifying underlying causes and tailoring a treatment plan (pharmacological or non-pharmacologic treatments including provision of staff education and support, training in problem solving, and targeted therapy directed at the underlying causes for specific behaviors).
During a 6-months period, patients will be included in both arms, whenever they present a disruptive NPS that requires a specialist consultation based on the long-term care facility (LTCF) staff judgment. In the intervention group, a telemedicine (TM) consultation between the LTCF staff (medical and nurse staff) and the Memory Center from the University Hospital, will occur at inclusion (T0). Then, a second TM consultation will occur at 1 month (T1). In the control group management of NPS will be done as usual care. In both groups, patients' parameters such as non-programmed hospitalizations and/or consultations due to disruptive NPS, psychotropic drugs use, and health costs, will be evaluated at inclusion, 1 month and at 2 months. Acceptability of the TM among the LTCF staff will be assessed during the study in the intervention group.
The two university hospitals are composed of a group of institutions for elderly people located near Toulouse and Limoges.
2,172 studies on the registry are indexed under Dementia; 540 are open to participants now.
This study's enrollment of 143 is above the median of 83 across 1,629 interventional studies indexed under Dementia.
Browse Dementia studies →University Hospital, Toulouse is the lead sponsor of 794 studies on the registry; 214 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
patients who will have normal care
patients who will have telemedicine
Procedure: telemedicine
psycho-behavioural care by telemedicine
Acceptability of the TM among the LTCF staff
Acceptability of the telemedicine (TM) among the LTCF staff which will be assessed in the intervention group by quantitative indicators (proportion of the solicitation of the TM solution among patients with disruptive NPS, the delay to obtain a TM consultation and the number of the staff participants at each TM consultation) and qualitative indicators (staff global satisfaction will be evaluated by focus groups and interviewing).
Time frame: 6 months
Rate of non-programmed hospitalizations and/or consultation due to disruptive NPS
Calculation of the rate of non-programmed hospitalizations and/or consultation due to disruptive NPS in both groups
Time frame: 6 months
The psychotropic drugs used
Description of psychotropic drugs used in both groups
Time frame: 6 months
describe the health costs
Description of the health costs in both groups
Time frame: 6 months
describe the estimation of the cluster effect ("design effect")
Estimation of the cluster effect ("design effect") in both groups
Time frame: 6 months
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Toulouse